Different structures and philosophies: EU and US -- Fragmented health funding -- US expenditure -- Private payers shift costs -- Cost sharing -- Generics -- Risk of federal negotiations -- Biomarkers -- Is value based pricing clear? -- Pricing, reimbursement and market access issues in Europe -- Current and future reimbursement mechanisms -- Why EU states intervene -- the dynamics of price versus reimbursement -- Effective way of reducing the cost of healthcare -- Launching new products -- EU countries and mechanisms of controlling their budget -- Pharmaeconomics -- Cost utility analysis and quality adjusted life year -- Politics, ethics and future reimbursement systems
